Berlin
Germany
171
2026-03-26
The entities that hold a legal rights for patent applications filed by inventor BERGMANN Andreas:
Andreas BERGMANN from Berlin, DE has applied for patents for these inventions. The list has both pending applications and granted patents:
FORMULATIONS AND DOSAGE AMOUNTS FOR ADMINISTERING AN ANTI-DPP3 ANTIBODY OR FRAGMENT THEREOF TO HUMANS
#2 | 2026-01-29PREDICTION OF AN INCREASE OF DPP3 IN A PATIENT WITH SEPTIC SHOCK
#3 | 2024-11-21METHODS FOR DETERMINING DPP3 AND THERAPEUTIC METHODS
#4 | 2024-11-07METHOD OF MODULATING THE ACTIVITY OF ADRENOMEDULLIN IN A SUBJECT IN NEED OF THERAPEUTIC INTERVENTION FOR ORGAN DYSFUNCTION OR ORGAN FAILURE ASSOCIATED WITH ADRENOMEDULLIN (ADM) ACTIVITY BY ADMINISTERING AN ANTI-ADRENOMEDULLIN (ADM) ANTIBODY OR AN ANTI-ADM FRAGMENT TO THE SUBJECT
#5 | 2024-08-15A METHOD FOR PREDICTING SEPSIS AND SEPTIC SHOCK
#6 | 2024-03-28Adrenomedullin assays and methods for determining mature andrendomedullin
#7 | 2024-03-14Adrenomedullin assays and methods for determining mature andrendomedullin
#8 | 2023-09-21DPP3 BINDER DIRECTED TO AND BINDING TO SPECIFIC DPP3-EPITOPES AND ITS USE IN THE PREVENTION OR TREATMENT OF DISEASES/ACUTE CONDITIONS THAT ARE ASSOCIATED WITH OXIDATIVE STRESS
#9 | 2023-08-10ANTI-ADRENOMEDULLIN (ADM) BINDER FOR USE IN THERAPY OF PATIENTS IN SHOCK
#10 | 2023-07-06DPP3 IN PATIENTS INFECTED WITH CORONAVIRUS
#11 | 2023-06-22DPP3 FOR THERAPY GUIDANCE, MONITORING AND STRATIFICATION OF NT-ADM ANTIBODIES IN PATIENTS WITH SHOCK
#12 | 2023-05-18USE OF PEPTIDYLGLYCINE ALPHA-AMIDATING MONOOXYGENASE (PAM) FOR THERAPEUTIC PURPOSE
#13 | 2023-05-11METHOD FOR PREDICTING THE RISK OF GETTING CANCER OR DIAGNOSING CANCER IN A FEMALE SUBJECT
#14 | 2023-04-27METHOD FOR PREDICTING THE RISK OF INCIDENCE OF CHRONIC KIDNEY DISEASE
#15 | 2023-04-06ANTI-ADRENOMEDULLIN (ADM) ANTIBODY OR ANTI-ADM ANTIBODY FRAGMENT OR ANTI-ADM NON-IG SCAFFOLD FOR USE IN THERAPY OR PREVENTION OF SHOCK
#16 | 2023-03-30METHODS FOR DETERMINING PEPTIDYLGLYCINE ALPHA-AMIDATING MONOOXYGENASE (PAM) AND ITS USE FOR DIAGNOSTIC PURPOSE
#17 | 2022-09-29THERAPY GUIDANCE AND/OR THERAPY MONITORING FOR TREATMENT OF SHOCK
#18 | 2022-09-15A METHOD FOR DIAGNOSING OR MONITORING KIDNEY FUNCTION OR DIAGNOSING KIDNEY DYSFUNCTION IN PEDIATRIC PATIENTS
#19 | 2022-08-25THERAPY MONITORING UNDER TREATMENT WITH AN ANTI-ADRENOMEDULLIN (ADM) BINDER
#20 | 2022-07-21ANTI-ADRENOMEDULLIN (ADM) BINDER FOR USE IN THERAPY OR PREVENTION OF SYMPTOMS OF ILLNESS
#21 | 2022-07-07THERAPY GUIDANCE AND/OR THERAPY MONITORING FOR A TREATMENT WITH ANGIOTENSIN-RECEPTOR-AGONIST AND/OR A PRECURSOR THEREOF
#22 | 2022-02-10SELENOPROTEIN P IN HEART FAILURE
#23 | 2021-10-28METHOD FOR DIAGNOSING OR MONITORING KIDNEY FUNCTION OR DIAGNOSING KIDNEY DYSFUNCTION
#24 | 2021-10-07Adrenomedullin assays and methods for determining mature adrenomedullin
#25 | 2021-09-16PRO-ADRENOMEDULLIN OR FRAGMENT THEREOF IN PATIENTS INFECTED WITH CORONA VIRUS AND TREATMENTS WITH BINDER AGAINST ADRENOMEDULLIN
#26 | 2021-07-22METHOD FOR THE DETECTION OF APOLIPOPROTEIN E4
#27 | 2021-07-08DPP3 binder directed to and binding to specific DPP3-epitopes and its use in the prevention or treatment of diseases / acute conditions that are associated with oxidative stress
#28 | 2021-04-15METHOD FOR PREDICTING THE RISK OF GETTING CANCER OR DIAGNOSING CANCER IN A FEMALE SUBJECT
#29 | 2021-01-14Method for predicting the risk of obesity in a subject
#30 | 2020-12-03Methods for determining DPP3 and therapeutic methods
#31 | 2020-11-05Selenoprotein P for prediction of a first cardiovascular event
#32 | 2020-10-15METHOD FOR PREDICTING THE RISK OF A SUBJECT FOR CONTRACTING DIABETES MELLITUS AND/OR METABOLIC SYNDROME OR FOR DIAGNOSING METABOLIC SYNDROME IN A SUBJECT
#33 | 2020-09-24METHOD FOR PREDICTING THE RISK OF GETTING A MAJOR ADVERSE CARDIAC EVENT
#34 | 2020-08-06ADRENOMEDULLIN TO GUIDE THERAPY OF BLOOD PRESSURE DECLINE
#35 | 2020-07-16hGH Determination for Use to Guide Prevention of a Major Adverse Cardiac Event or a Cardiovascular Disease in a Subject
#36 | 2020-06-11A METHOD FOR DIAGNOSING OR MONITORING KIDNEY FUNCTION OR DIAGNOSING KIDNEY DYSFUNTION
#37 | 2020-02-13FASTING LEVELS OF GROWTH HORMONE AS A PREDICTIVE MARKER OF CARDIOVASCULAR RISK
#38 | 2019-12-12ADRENOMEDULLIN FOR ASSESSING CONGESTION IN A SUBJECT WITH ACUTE HEART FAILURE
#39 | 2019-07-25Use of procalcitonin (PCT) in risk stratification and prognosis of patients with a primary, non-infectious disease
#40 | 2019-05-16METHODS FOR DETERMINING DPP3 AND THERAPEUTIC METHODS
#41 | 2019-03-28Method of modulating the adrenomedullin (ADM) activity of a patient by administering to the patient an anti-ADM antibody or fragment thereof that specifically binds to mature human ADM
#42 | 2019-02-14Method for diagnosing or monitoring kidney function or diagnosing kidney dysfunction
#43 | 2019-01-10Anti-adrenomedullin (ADM) monoclonal antibodies and anti-ADM monoclonal antibody fragments that bind to adrenomedullin
#44 | 2018-08-30Method for predicting the risk of obesity in a subject
#45 | 2018-05-24DETERMINATION OF A MIDREGIONAL PROADRENOMEDULLIN PARTIAL PEPTIDE IN BIOLOGICAL FLUIDS FOR DIAGNOSTIC PURPOSES, AND IMMUNOASSAYS FOR CARRYING OUT SUCH A DETERMINATION
#46 | 2018-05-10Method for predicting the risk of incidence of chronic kidney disease
#47 | 2018-02-22RISK ASSESSMENT FOR ANTIBIOTICS TREATMENT IN PATIENTS SUFFERING FROM PRIMARY NON-INFECTIOUS DISEASE BY DETERMINING THE LEVEL OF PROCALCITONIN
#48 | 2017-10-26METHOD FOR PREDICTING THE RISK OF GETTING CANCER OR DIAGNOSING CANCER IN A FEMALE SUBJECT
#49 | 2017-09-14Method for diagnosing or monitoring kidney function or diagnosing kidney dysfunction
#50 | 2017-08-24DIAGNOSTIC METHOD FOR DISORDERS USING COPEPTIN
#51 | 2017-08-17hGH Determination for Use to Guide Prevention of a Major Adverse Cardiac Event or a Cardiovascular Disease in a Subject
#52 | 2017-03-02Diagnosis and risk stratification of infections and chronic diseases of the respiratory tract and lungs by means of provasopressin, particularly copeptin or neurophysin II
#53 | 2017-02-23Adrenomedullin assays and methods for determining mature adrenomedullin
#54 | 2017-01-12Adrenomedullin to guide therapy of blood pressure decline
#55 | 2016-11-10Neurokinin-1 Receptor Antagonists For Use In A Method Of Prevention Of Cancer
#56 | 2016-11-03Adrenomedullin binder for use in therapy of cancer
#57 | 2016-09-01A METHOD FOR PREDICTING THE RISK OF GETTING A MAJOR ADVERSE CARDIAC EVENT
#58 | 2016-06-23Method of modulating the activity of adrenomedullin in a subject in need of therapeutic intervention for organ dysfunction or organ failure associated with adranomedullin (ADM) activity by administering an anti-adrenomedullin (ADM) antibody or an anti-ADM antibody fragment to the subject
#59 | 2016-06-16Diagnosis and Risk Assessment of Pancreatic Diabetes Using MR-proADM
#60 | 2016-06-09DIAGNOSIS AND RISK STRATIFICATION USING NT-proET-1
#61 | 2016-06-09Methods of modulating the activity of adrenomedullin in a subject in need of regulation of fluid balance by administering an anti-adrenomedullin (ADM) antibody or an anti-ADM antibody fragment
#62 | 2016-05-12Method for risk stratification in stable coronary artery disease
#63 | 2016-05-12In vitro method for early or differential diagnosis or prognosis of myocardial infarction in a patient
#64 | 2016-04-07Method for diagnosis of dementias and neuroinflammatory diseases based on an increased level of procalcitonin in cerebrospinal fluid
#65 | 2016-04-07METHOD FOR STRATIFYING A FEMALE SUBJECT FOR HORMONE REPLACEMENT THERAPY
#66 | 2015-12-03Method for predicting the risk of getting cancer or diagnosing cancer in a subject
#67 | 2015-10-15Arginine vasopressin pro-hormone as predictive biomarker for diabetes
#68 | 2015-09-24Method for predicting the risk of getting cancer or diagnosing cancer in a female subject
#69 | 2015-09-17Method for diagnosing or monitoring kidney function or diagnosing kidney dysfunction
#70 | 2015-09-03Risk assessment for antibiotics treatment in patients suffering from primary non-infectious disease by determining the level of procalcitonin
#71 | 2015-07-09METHODS OF DIAGNOSIS AND RISK STRATIFICATION OF ADVERSE EVENTS IN POST MYOCARDIAL INFARCTION PATIENTS USING PRO-ADRENOMEDULLIN
#72 | 2015-04-30Method for Predicting the Risk of Getting a Cardiovascular Event in a Female Subject
#73 | 2015-03-26Method for risk stratification in stable coronary artery disease
#74 | 2015-02-26Method for predicting the risk of a subject for contracting diabetes mellitus and/or metabolic syndrome or for diagnosing metabolic syndrome in a subject
#75 | 2015-01-29Method for Predicting the Risk of Getting Cancer or Diagnosing Cancer in a Female Subject
#76 | 2015-01-08Diagnosis and risk stratification by determining the marker CT-proADM
#77 | 2014-11-06ANTI-ADRENOMEDULLIN (ADM) ANTIBODY OR ANTI-ADM ANTIBODY FRAGMENT OR ANTI-ADM NON-IG SCAFFOLD FOR PREVENTION OR REDUCTION OF ORGAN DYSFUNCTION OR ORGAN FAILURE IN A PATIENT HAVING A CHRONIC OR ACUTE DISEASE OR ACUTE CONDITION
#78 | 2014-10-30Adrenomedullin assays and methods for determining mature adrenomedullin
#79 | 2014-10-30Determination of a midregional proadrenomedullin partial peptide in biological fluids for diagnostic purposes, and immunoassays for carrying out such a determination
#80 | 2014-10-30Methods of modulating adrenomedullin by administering an anti-adrenomedullin (ADM) antibody
#81 | 2014-10-23ANTI-ADRENOMEDULLIN (ADM) ANTIBODY OR ANTI-ADM ANTIBODY FRAGMENT OF ANTI-ADM NON-IG SCAFFOLD FOR REGULATING THE FLUID BALANCE IN A PATIENT HAVING A CHRONIC OR ACUTE DISEASE
#82 | 2014-02-20BIOMARKERS FOR THE PREDICTION OF INCIDENT CANCER
#83 | 2014-01-16Prognosis and risk assessment in stroke patients by determining the level of marker peptides
#84 | 2013-12-26Diagnosis of acute coronary syndrome, myocardial infarction, or angina pectoris by means of neurophysin II
#85 | 2013-10-10Diagnosis and risk stratification by determining the marker CT-proADM
#86 | 2013-08-01Anti-adrenomedullin (ADM) antibody or anti-ADM antibody fragment for use in therapy
#87 | 2013-08-01Anti-adrenomedullin (ADM) antibody or anti-ADM antibody fragment or anti-ADM non-IG scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition
#88 | 2013-05-16Method for the selective detection and measurement of procalcitonin 1-116 and amino-terminal peptides of procalcitonin comprising amino acids 1 and 2 of procalcitonin 1-116
#89 | 2012-10-25DIAGNOSIS AND RISK STRATIFICATION OF INFECTIONS AND CHRONIC DISEASES OF THE RESPIRATORY TRACT AND LUNGS BY MEANS OF PROVASOPRESSIN, PARTICULARLY COPEPTIN OR NEUROPHYSIN II
#90 | 2012-10-18Method for the determination of the formation of endothelins for medical diagnostic purposes, and antibodies and kits for carrying out such a method
#91 | 2012-06-07Vasoactive hormone-based stratification of patients suffering from diseases related to endothelial function/dysfunction
#92 | 2012-05-17Method for risk stratification in stable coronary artery disease
#93 | 2012-04-26Risk assessment for antibiotics treatment in patients suffering from primary non-infectious disease by determining the level of procalcitonin
#94 | 2012-04-05Detection of bacterial infections in subjects suffering from dyspnea
#95 | 2012-03-29Use of carbamoyl phosphate synthetase 1 (CPS) as a humoral biomarker for the diagnosis of tumour diseases and chronic inflammatory intestinal diseases
#96 | 2012-01-05BIOMARKER FOR THE PREDICTION OF FIRST ADVERSE EVENTS
#97 | 2012-01-05IN VITRO-METHOD FOR THE DIAGNOSIS, PROGNOSIS, MONITORING AND THERAPY FOLLOW-UP OF DISORDERS ASSOCIATED WITH THE METABOLIC SYNDROME, A CARDIOVASCULAR DISEASE AND/OR INSULIN RESISTANCE
#98 | 2011-12-29Arginine vasopressin pro-hormone as predictive biomarker for diabetes
#99 | 2011-11-10Use of precursors of tachykinins and/or their fragments in medical diagnostic
#100 | 2011-10-27PROGNOSIS AND RISK ASSESSMENT IN STROKE PATIENTS BY DETERMINING THE LEVEL OF MARKER PEPTIDES
247735 ⎘